You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. A biomarker of aging as a predictor of kidney transplant function

    SBC: HEALTHSPAN DIAGNOSTICS, LLC            Topic: NIA

    ABSTRACT The number of kidney transplant candidates on the waiting list continues to increase each year, while the number of kidney donations remains stagnant. The enduring donor shortage compels clinicians to use kidneys from marginal donors, referred toas expanded criteria donors (ECD). ECD kidneys, obtained primarily from older donors, have a higher risk of delayed graft function and graft loss ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Fungal Metabolites as Novel Anthelmintics against Soil-Transmitted Helminthes.

    SBC: Mycosynthetix, Inc.            Topic: NIAID

    DESCRIPTION (provided by applicant): Title: Fungal Metabolites as Novel Anthelmintics against Soil-Transmitted Helminthes Project Summary/Abstract It is estimated that over 2 billion people worldwide are suffering from complications due to infections withsoil transmitted helminthes (STHs), but very little research is being conducted by human health pharmaceutical companies. In the USA, it is estim ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Antifungal Compound Discovery from Metagenomes

    SBC: LUCIGEN CORPORATION            Topic: NIAID

    DESCRIPTION (provided by applicant): There is societal need for new compounds in our arsenal of defenses against fungal pathogens, many of which are increasingly resistant to existing therapeutics. The best possible source for new antifungal compounds withpotentially novel mechanisms of action is within natural environments, particularly soils, which have the greatest diversity of microbial life. ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Biosensor Assays for Diagnosis of Chronic HCV Infection

    SBC: ALDERON BIOSCIENCES, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): This Phase I SBIR application is submitted in response to the call by DHHS for new tests for qualitative measurement of HCV RNA for diagnosis of chronic HCV infection in patients. The need is for HCV RNA assays that areas reliable but less expensive and resource-demanding than current molecular assays. The new test proposed for research and development consists ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Novel system for sensitive detection of botulinum neurotoxins

    SBC: ALPHA UNIVERSE LLC            Topic: NIAID

    DESCRIPTION (provided by applicant): The existence of terrorist organizations around the world, along with their ability to recruit expertise from physicians and scientists, poses an increasing threat of bioterrorist attack to society. In order to reduce the consequences of such an attack or even prevent it, new systems for detection of biothreat agents are necessary. Currently existing express ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Cell analysis and immunoassay device for distributed HIV diagnosis and monitoring

    SBC: INDEXUS BIOMEDICAL, LLC            Topic: NIAID

    DESCRIPTION (provided by applicant): The goal of this research is to develop a new approach to bring diagnosis and monitoring tests for HIV to the primary care level (primary care provider office, small healthcare clinics and labs, and community health center labs) by introducing a multi-functional cell analysis and immunoassay platform that is portable, low cost and easy to use. It will allow pat ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Optimization of an innate immune stimulating adjuvant for an HIV DNA vaccine

    SBC: PROFECTUS BIOSCIENCES, INC.            Topic: NIAID

    DESCRIPTION: There is a growing consensus that protection against HIV infection will require BOTH antiviral antibody responses as well as polyfunctional CD4+ and CD8+ T cells with potent lytic activity. To stimulate the breadth, potency, and rate of response required, Profectus Biosciences intends to utilize its platform technologies based on electroporation of DNA vaccines combined with genetic a ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Evaluation of Novel Cyclophilin D Inhibitors for Mitochondrial Disease Therapy

    SBC: SCYNEXIS, INC.            Topic: NIAMS

    DESCRIPTION (provided by applicant): Myopathies and other clinical disorders arising from genetic abnormalities of the mitochondrial respiratory chain collectively affect as many as 1 in 8000 individuals, representing in aggregate a significant disease burden, even though the specific underlying genetic lesions are each quite rare. Despite the need for therapeutic strategies to prevent or slow the ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Stem cell therapy for improved fixation of cementless total hip replacements

    SBC: AFFINERGY, LLC            Topic: NIAMS

    DESCRIPTION (provided by applicant): Through modern surgical advancements, total hip replacements (THR) have become one of the most successful implant procedures to date. Even though long-term success rates are high, the staggering number of THR proceduresper annum (~200,000 in the United States alone) results in thousands of failed implants each year. Most implants fail through aseptic loosening ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. BAC Sudoku Sequencing Paradigm to Accelerate Metagenomic Natural Product Chemistr

    SBC: LUCIGEN CORPORATION            Topic: NCCIH

    DESCRIPTION (provided by applicant): There is societal need for new compounds in our arsenal of defenses against microbial pathogens, many of which are increasingly resistant to existing therapeutics. The best possible source for new antimicrobial compounds with potentially novel mechanisms of action is within natural environments, particularly soils, which have the greatest diversity of microbial ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government